Kailera officer granted 175,000 stock options

Q: What did Kathleen Tregoning acquire in this Form 4 for KLRA?

She received a grant of stock options for 175,000 shares of Kailera Therapeutics common stock. These are compensation-related options, not open-market purchases, and give her the right to buy shares at a fixed exercise price.

Q: What is the exercise price of the new KLRA stock options?

The options have an exercise price of $23.30 per share. This is the price at which Kathleen Tregoning can purchase Kailera Therapeutics common stock if and when the options become vested and she chooses to exercise them.

Q: How do the newly granted KLRA options vest for Kathleen Tregoning?

The options vest as to 25% of the underlying shares on June 29, 2027. The remaining shares vest in 36 substantially equal monthly installments, conditioned on her continued service through each vesting date.

Q: When do Kathleen Tregoning’s KLRA stock options expire?

The stock options expire on July 6, 2036. After that date, any unexercised portion of the 175,000-share grant can no longer be used to purchase Kailera Therapeutics common stock at the stated exercise price.

Q: How many KLRA stock options does Kathleen Tregoning hold after this transaction?

After this grant, she holds stock options for 175,000 underlying shares directly. This Form 4 reflects a compensation-related award rather than a sale or open-market purchase of Kailera Therapeutics stock.

Kailera Therapeutics, Inc. reported that officer Kathleen Tregoning received a grant of stock options covering 175,000 shares of common stock.

Accepted by SEC EDGAR 07/08/2026 - 04:20 PM EDT

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Kailera Therapeutics, Inc. reported that officer Kathleen Tregoning received a grant of stock options covering 175,000 shares of common stock. The options have an exercise price of $23.30 per share and expire on July 6, 2036.

These options vest as to 25% of the underlying shares on June 29, 2027 and then in 36 substantially equal monthly installments, subject to her continued service. Following this grant, she holds stock options exercisable for 175,000 shares directly.

Insider Trade Summary

Grant/Award: 175,000 shares

Grant/Award 1 txn

Insider Tregoning Kathleen

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	175,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 175,000 contracts (Direct)

Holdings Before and After: Stock Option (right to buy), 0 to 175,000 contracts (Direct)

Footnotes (1)

F1. The options vest and become exercisable as to 25% of the underlying shares on June 29, 2027 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service through each such vesting date.

Key Figures

Option grant size: 175,000 options Exercise price: $23.30 per share Expiration date: July 6, 2036 +3 more

6 metrics

Option grant size 175,000 options Grant covering 175,000 underlying common shares

Exercise price $23.30 per share Stock option exercise price

Expiration date July 6, 2036 Option expiration

Initial vesting tranche 25% of shares Vests on June 29, 2027

Monthly vesting installments 36 installments Remaining options vest monthly after June 29, 2027

Options held after grant 175,000 options Total stock options following transaction

Key Terms

Stock Option (right to buy), exercise price, expiration date, vest and become exercisable

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 23.3000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-07-06T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vest and become exercisable financial

"The options vest and become exercisable as to 25% of the underlying shares"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Kathleen Tregoning acquire in this Form 4 for KLRA?

She received a grant of stock options for 175,000 shares of Kailera Therapeutics common stock. These are compensation-related options, not open-market purchases, and give her the right to buy shares at a fixed exercise price.

What is the exercise price of the new KLRA stock options?

The options have an exercise price of $23.30 per share. This is the price at which Kathleen Tregoning can purchase Kailera Therapeutics common stock if and when the options become vested and she chooses to exercise them.

How do the newly granted KLRA options vest for Kathleen Tregoning?

The options vest as to 25% of the underlying shares on June 29, 2027. The remaining shares vest in 36 substantially equal monthly installments, conditioned on her continued service through each vesting date.

When do Kathleen Tregoning’s KLRA stock options expire?

The stock options expire on July 6, 2036. After that date, any unexercised portion of the 175,000-share grant can no longer be used to purchase Kailera Therapeutics common stock at the stated exercise price.

How many KLRA stock options does Kathleen Tregoning hold after this transaction?

After this grant, she holds stock options for 175,000 underlying shares directly. This Form 4 reflects a compensation-related award rather than a sale or open-market purchase of Kailera Therapeutics stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tregoning Kathleen

(Last)

(First)

(Middle)

C/O KAILERA THERAPEUTICS, INC.

180 THIRD AVENUE, 4TH FLOOR

(Street)

WALTHAM

MASSACHUSETTS

02451

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kailera Therapeutics, Inc. [ KLRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$23.3	07/06/2026		A		175,000		⁽¹⁾	07/06/2036	Common Stock	175,000	$0	175,000	D

Explanation of Responses:

1. The options vest and become exercisable as to 25% of the underlying shares on June 29, 2027 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service through each such vesting date.

Remarks:

Chief Corporate Affairs Officer

	/s/ John Mei, Attorney-in-fact	07/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR